The delivery of miR‐1915‐3p via exosomes significantly restored oxaliplatin sensitivity in CRC cells by suppressing EMT‐promoting oncogenes (PFKFB3 and USP2), reducing cell migration, invasion, and enhancing apoptosis both in vitro and in vivo.[102] Similarly, exosomal circ‐FBXW7 was investigated for its ability to reverse oxaliplatin resistance in CRC. The gene discussed is USP2; the disease is colorectal carcinoma.